The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is a National Cancer Institute-designated comprehensive cancer center located in Baltimore, Maryland.

During the past decade, University of Maryland, Greenebaum Cancer Center conducted 225 clinical trials. In the 10-year time frame, 225 clinical trials started and 215 clinical trials were completed, i.e. on average, 95.6% percent of trials that started reached the finish line to date. In the past 5 years, 87 clinical trials started and 89 clinical trials were completed. i.e. 102.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Maryland, Greenebaum Cancer Center" #1 sponsor was "National Cancer Institute (NCI)" with 133 trials, followed by "Alliance for Clinical Trials in Oncology" with 75 trials sponsored, "Children's Oncology Group" with 61 trials sponsored, "Radiation Therapy Oncology Group" with 46 trials sponsored and "NRG Oncology" with 46 trials sponsored. Other sponsors include 255 different institutions and companies that sponsored additional 133 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Maryland, Greenebaum Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 284 trials as a collaborator, "NRG Oncology" with 47 trials as a collaborator, "SWOG Cancer Research Network" with 15 trials as a collaborator, "Cancer and Leukemia Group B" with 13 trials as a collaborator and "Radiation Therapy Oncology Group" with 12 trials as a collaborator. Other collaborators include 142 different institutions and companies that were collaborators in the rest 78 trials.

According to Clinical.Site data, the most researched conditions in "University of Maryland, Greenebaum Cancer Center" are "Lung Cancer" (33 trials), "Breast Cancer" (31 trials), "Leukemia" (30 trials), "Lymphoma" (28 trials) and "Multiple Myeloma" (20 trials). Many other conditions were trialed in "University of Maryland, Greenebaum Cancer Center" in a lesser frequency.

Most popular intervention types in "University of Maryland, Greenebaum Cancer Center" are "Drug" (485 trials), "Other" (202 trials), "Biological" (168 trials), "Radiation" (148 trials) and "Procedure" (98 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (108 trials), "Quality-of-Life Assessment" (55 trials), "Cyclophosphamide" (39 trials), "radiation therapy" (38 trials) and "Carboplatin" (34 trials). Other intervention names were less common.

The vast majority of trials in "University of Maryland, Greenebaum Cancer Center" are 505 trials for "All" genders, 54 trials for "Female" genders and 42 trials for "Male" genders.

Currently, there are NaN active trials in "University of Maryland, Greenebaum Cancer Center". undefined are not yet recruiting, 90 are recruiting, 138 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 292 completed trials in University of Maryland, Greenebaum Cancer Center, 7 suspended trials, and 59 terminated clinical trials to date.

Out of the total trials that were conducted in University of Maryland, Greenebaum Cancer Center, 114 "Phase 1" clinical trials were conducted, 265 "Phase 2" clinical trials and 230 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 17 trials that are defined as “Not Applicable".